Clinical Trial Update: Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating intranasal oxytocin delivered by a novel device in adults with autism spectrum disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• Oxytocin (Oxytocin)

Snippet

Sponsor: OptiNose AS | Conditions: Autism Spectrum Disorder | Phase 1, Phase 2 | Status: COMPLETED